Gathering the record
Relay is organizing the evidence and source boundaries.
Informal four-component blend label
KLOW is a community label commonly used for a mixture described as GHK-Cu, BPC-157, TB-500, and KPV. No study was located testing all four together.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
KLOW is a community label for a mixture usually described as GHK-Cu, BPC-157, TB-500, and KPV. The name does not define one standardized research product.
The mixture brings several repair and inflammation hypotheses together. That complexity increases—not reduces—the need for direct evidence about identity, compatibility, exposure, interactions, and safety.
Relay found no controlled or registered study testing all four ingredients together. Component evidence is uneven: some topical human GHK-Cu research exists, while BPC-157 remains limited and TB-500 and KPV lack identified human administration evidence. Separate findings cannot demonstrate a four-part effect.
The exact formula, stability, sterility, pharmacokinetics, interactions, immunogenicity, safety, and clinical outcomes remain unknown. Products sold under the same community name may not share an identity, so the section cannot honestly present one studied formulation.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
No verified study was located that administered the four named components together as one reproducible KLOW formulation. Ingredient-level evidence cannot establish a mixture result.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The available record consists of four separate ingredient records and documented searches that found no exact-combination study.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No direct evidence establishes benefit, synergy, compatibility, stability, safety, or pharmacokinetics for the four-component mixture.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Two named components lack identified human administration evidence, and the better-studied component records use different formulations and routes. The section remains incomplete because no blend-specific identity, compatibility, exposure, safety, or outcome record was found. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
None for KLOW as a blend. The strongest component-level human evidence comes from specific topical GHK-Cu studies; it cannot establish injectable KLOW.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The blend's identity and ratio, chemical and physical compatibility, stability after mixing, sterility, pharmacokinetics, interactions, immunogenicity, dose-response, safety, and clinical effects.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Peptide Relay uses KLOW to organize discussion of mixtures labeled as GHK-Cu, BPC-157, TB-500, and KPV. The name does not define a regulator-recognized identity, fixed ratio, formulation, or quality standard.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a study administering all four together.
KPV findings come from cell systems, mouse inflammatory models, engineered delivery systems, and excised skin. They do not show that KPV improves the other ingredients or the mixture.
FDA found no TB-500 or KPV administration to humans by any route. The remaining component records are also formulation- and route-specific and do not establish the blend.
Only four people received the two-material treatment, no one received GHK-Cu or KPV, there was no comparison group, and the report does not verify TB-500 identity.
Separate mechanisms do not show that four peptides remain chemically stable together, avoid aggregation, retain potency, or produce a favorable biological interaction.
No approved fixed-combination product or combination study provides a universal preparation, administration, or handling process.
The four named components have distinct regulatory histories. Advisory votes or category placement for an ingredient do not establish approval, safety, effectiveness, or compounding eligibility of the mixture.
Mechanisms
KLOW combines four proposed components with materially different identities and evidence records. GHK-Cu human evidence is mainly topical and formulation-specific. BPC-157 has predominantly preclinical evidence, small uncontrolled human reports, and a registered Phase 2 trial without results. FDA located no human TB-500 or KPV administration by any route. KPV's inflammatory findings come from cell systems, animal models, engineered delivery formulations, and excised skin. No pharmacokinetic, compatibility, stability, interaction, safety, or efficacy study of the exact four-component mixture was located.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized topical GHK-Cu program with standardized diabetic-ulcer care
Adults with diabetic neuropathic plantar ulcers
An immediate-treatment plantar-ulcer analysis reported more complete closure with topical GHK-Cu than vehicle.
Study administration: Topical GHK-Cu gel plus wound care versus vehicle plus wound care
Limitations: This tested topical GHK-Cu in a defined wound population. It did not test BPC-157, TB-500, KPV, injection, mixing, or KLOW.
TB-500 metabolism in human-derived in-vitro systems and rats, with fibroblast scratch-wound assays
Human serum and microsomal systems, cultured fibroblasts, and rats
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Study administration: TB-500 free base and synthesized metabolites under laboratory protocols
Limitations: This is laboratory and animal TB-500 evidence. It does not establish human benefit or any finding for a four-component mixture.
Uncontrolled retrospective report of intra-articular treatment for knee pain
16 people with several types of knee pain
Fourteen of 16 people reported relief overall. Three of the four people in the two-material subgroup reported relief.
Study administration: Twelve received BPC-157 alone; four also received material described as thymosin beta-4. No GHK-Cu or KPV was used.
Limitations: There was no control group, GHK-Cu, or KPV. The four-person two-material subgroup cannot establish a combination effect, and the thymosin-beta-4 identity was not verified as TB-500.
Transport experiments in intestinal and immune-cell lines plus chemically induced mouse colitis models
Caco2-BBE and HT29-Cl.19A intestinal cells, Jurkat T cells, and mice with experimental colitis
The study reported PepT1-mediated cellular uptake, reduced inflammatory signaling in cell models, and reduced inflammation in mouse colitis models.
Study administration: KPV exposure in cell systems and oral KPV in mouse colitis models
Limitations: Cell-line transport and mouse-colitis findings do not establish human KPV exposure, wound healing, injection effects, or any result for KLOW.
Randomized, double-blind, placebo-controlled BPC-157 trial with standardized rehabilitation
Adults aged 18–45 with MRI-confirmed acute grade II hamstring strain
No results are posted. The registration cannot establish benefit for BPC-157 or for any blend.
Study administration: Protocol-defined subcutaneous investigational BPC-157 or placebo; no GHK-Cu, TB-500, or KPV
Limitations: This is an unfinished BPC-157-only trial. It provides no evidence about KLOW, compatibility, or four-component effects.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNo FDA-approved GHK-Cu/BPC-157/TB-500/KPV fixed-combination product was located. Ingredient-level compounding reviews and advisory actions do not approve the blend. The blend's identity and ratio, chemical and physical compatibility, stability after mixing, sterility, pharmacokinetics, interactions, immunogenicity, dose-response, safety, and clinical effects.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-25
2026-07-25
2026-07-24
2026-07-23
2026-07-21
2026-05-14
2026-05-12
2026-02-27 · NCT07437547
2024-03-15 · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
2021-07-01 · PMID 34324435
2008-01-01 · PMID 18061177 · DOI 10.1053/j.gastro.2007.10.026
1994-10-01 · PMID 17147644 · DOI 10.1046/j.1524-475X.1994.20406.x
No direct primary administration source was verified for this exact identity. The limitation is the finding.